Literature DB >> 8669956

Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet.

A MacDonald1, G Rylance, S K Hall, D Asplin, I W Booth.   

Abstract

The optimal dietary management of children with phenylketonuria (PKU) has rarely been rigorously explored. The aim of this study was to assess longitudinally the effects of three factors thought to influence plasma phenylalanine concentrations in PKU: total energy intake; protein intake from natural foods allowed freely in addition to allocated phenylalanine exchanges; and the distribution of protein substitute throughout the day. Nineteen subjects, 15 girls and four boys aged 1-16 years, were enrolled. Food intake was weighed, and twice daily plasma phenylalanine concentrations measured during either 3-day or 4-day periods, for a total of 21 days throughout six months. There was a negative correlation between the percentage of protein substitute eaten by the time of the evening meal and the fall in plasma phenylalanine concentration during the day (r = -0.941; p < 0.0001). On average, 49% of pre-evening meal plasma phenylalanine concentrations were less than 100 mumol/l in children who had taken at least 65% of their protein substitute by the time of their evening meal. There was no correlation between excess natural protein intake from freely allowed foods and (a) pre-breakfast or pre-evening meal plasma phenylalanine concentrations or (b) the daily change between pre-breakfast and pre-evening meal concentrations. Nor was there any correlation between excess natural protein intake on the previous day and plasma phenylalanine concentration on the following morning. Energy intake was not correlated with plasma phenylalanine concentrations. It is therefore preferable to distribute the protein substitute evenly through the day in order to achieve stable phenylalanine concentrations, rather than to carry out further fine manipulation of the phenylalanine intake, which would make management of the diet even more difficult.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669956      PMCID: PMC1511531          DOI: 10.1136/adc.74.5.412

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  15 in total

1.  Behavior disturbance in 8-year-old children with early treated phenylketonuria. Report from the MRC/DHSS Phenylketonuria Register.

Authors:  I Smith; M G Beasley; O H Wolff; A E Ades
Journal:  J Pediatr       Date:  1988-03       Impact factor: 4.406

2.  Linguistic development of children with phenylketonuria and normal intelligence.

Authors:  C R Melnick; K K Michals; R Matalon
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

3.  Preliminary report on inverse diurnal variation of phenylalanine: implications in maternal phenylketonuria.

Authors:  D L Farquhar; F Steven; A Westwood
Journal:  Hum Nutr Appl Nutr       Date:  1985-06

4.  Intelligence and quality of dietary treatment in phenylketonuria.

Authors:  I Smith; M G Beasley; A E Ades
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

5.  HPLC measurement of phenylalanine in plasma.

Authors:  N D Atherton; A Green
Journal:  Clin Chem       Date:  1988-11       Impact factor: 8.327

6.  Brain MRI changes in phenylketonuria. Associations with dietary status.

Authors:  A J Thompson; S Tillotson; I Smith; B Kendall; S G Moore; D P Brenton
Journal:  Brain       Date:  1993-08       Impact factor: 13.501

7.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

8.  Neuropsychological deficits in early treated phenylketonuric children.

Authors:  B F Pennington; W J van Doorninck; L L McCabe; E R McCabe
Journal:  Am J Ment Defic       Date:  1985-03

9.  Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents.

Authors:  H C Lou; F Güttler; C Lykkelund; P Bruhn; A Niederwieser
Journal:  Eur J Pediatr       Date:  1985-05       Impact factor: 3.183

10.  Neurological deterioration in young adults with phenylketonuria.

Authors:  A J Thompson; I Smith; D Brenton; B D Youl; G Rylance; D C Davidson; B Kendall; A J Lees
Journal:  Lancet       Date:  1990-09-08       Impact factor: 79.321

View more
  26 in total

1.  Behavioural factors related to metabolic control in patients with phenylketonuria.

Authors:  M R Crone; F J van Spronsen; K Oudshoorn; J Bekhof; G van Rijn; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Use of Gastrostomy Tube to Prevent Maternal PKU Syndrome.

Authors:  Jessica A Scott Schwoerer; Lisa Obernolte; Sandra Van Calcar; Susan Heighway; Heather Bankowski; Phillip Williams; Gregory Rice
Journal:  JIMD Rep       Date:  2012-01-31

3.  Dietary protein counting as an alternative way of maintaining metabolic control in phenylketonuria.

Authors:  A L Sweeney; R M Roberts; J M Fletcher
Journal:  JIMD Rep       Date:  2011-09-16

4.  Nutritional Management of Phenylketonuria.

Authors:  Erin L Macleod; Denise M Ney
Journal:  Ann Nestle Eng       Date:  2010-06

5.  Does a single plasma phenylalanine predict quality of control in phenylketonuria?

Authors:  A MacDonald; G W Rylance; D Asplin; S K Hall; I W Booth
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

Review 6.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

Review 7.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

Review 8.  Protein substitutes for PKU: what's new?

Authors:  A Macdonald; A Daly; P Davies; D Asplin; S K Hall; G Rylance; A Chakrapani
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 9.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

10.  Benefits of normalizing plasma phenylalanine: impact on behaviour and health. A case report.

Authors:  K Williams
Journal:  J Inherit Metab Dis       Date:  1998-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.